Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Biomerica Management

Management Kriterienprüfungen 4/4

Biomerica's CEO ist Zack Irani , ernannt in Apr 1997, hat eine Amtszeit von 27.08 Jahren. Die jährliche Gesamtvergütung beträgt $141.25K , bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.07% der Aktien des Unternehmens, im Wert von $608.25K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.6 Jahre bzw. 6.1 Jahre.

Wichtige Informationen

Zack Irani

Geschäftsführender

US$141.3k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	100.0%
Amtszeit als Geschäftsführer	27.1yrs
Eigentum des Geschäftsführers	6.1%
Durchschnittliche Amtszeit des Managements	2.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.1yrs

Jüngste Management Updates

Recent updates

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Jul 14

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Dec 03

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

Dec 02

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Sep 15

Biomerica (BMRA) Investor Presentation - Slideshow

Jun 14

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Jun 13

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Apr 04

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

Mar 08

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Feb 10

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Jan 15

Biomerica soars as its COVID-19 antigen test wins European nod

Jan 12

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

Dec 20

Biomerica clinical trial for IBS nears enrollment completion

Dec 09

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Nov 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Zack Irani im Vergleich zu den Einnahmen von Biomerica verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Feb 29 2024	n/a	n/a	-US$6m
Nov 30 2023	n/a	n/a	-US$6m
Aug 31 2023	n/a	n/a	-US$6m
May 31 2023	US$141k	US$141k	-US$7m
Feb 28 2023	n/a	n/a	-US$7m
Nov 30 2022	n/a	n/a	-US$6m
Aug 31 2022	n/a	n/a	-US$5m
May 31 2022	US$491k	US$135k	-US$5m
Feb 28 2022	n/a	n/a	-US$4m
Nov 30 2021	n/a	n/a	-US$7m
Aug 31 2021	n/a	n/a	-US$7m
May 31 2021	US$488k	US$137k	-US$7m
Feb 28 2021	n/a	n/a	-US$6m
Nov 30 2020	n/a	n/a	-US$5m
Aug 31 2020	n/a	n/a	-US$4m
May 31 2020	US$330k	US$137k	-US$2m
Feb 29 2020	n/a	n/a	-US$3m
Nov 30 2019	n/a	n/a	-US$2m
Aug 31 2019	n/a	n/a	-US$2m
May 31 2019	US$329k	US$137k	-US$2m
Feb 28 2019	n/a	n/a	-US$2m
Nov 30 2018	n/a	n/a	-US$2m
Aug 31 2018	n/a	n/a	-US$2m
May 31 2018	US$295k	US$137k	-US$1m
Feb 28 2018	n/a	n/a	-US$1m
Nov 30 2017	n/a	n/a	-US$1m
Aug 31 2017	n/a	n/a	-US$1m
May 31 2017	US$137k	US$137k	-US$909k

Vergütung im Vergleich zum Markt: ZackDie Gesamtvergütung ($USD141.25K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD668.06K).

Entschädigung vs. Einkommen: ZackDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Zack Irani (57 yo)

27.1yrs

Amtszeit

US$141,250

Vergütung

Mr. Zackary S. Irani, also known as Zack, has been Chief Executive Officer of Biomerica Inc. since April 29, 1997 and is its Director and served as its President. He was Chairman of the Board at Biomerica...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zackary Irani	CEO & Director	27.1yrs	US$141.25k	6.07% $ 638.9k
Allen Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary	24.6yrs	US$126.25k	0.55% $ 58.4k
Gary Lu	Principal Accounting Officer & CFO	1.2yrs	US$400.10k	keine Daten
Lucy Liu	Director of Manufacturing & Technical Operations	no data	keine Daten	keine Daten
Robert Carlson	Chief Commercial Officer	1.8yrs	keine Daten	keine Daten

2.6yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: BMRADas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Zackary Irani	CEO & Director	no data	US$141.25k	6.07% $ 638.9k
Allen Barbieri	Executive Vice-Chairman of the Board & Corporate Secretary	24.6yrs	US$126.25k	0.55% $ 58.4k
Edward Barnholt	Chairman of Strategic Advisory Board	7.8yrs	keine Daten	keine Daten
Harry Leider	Member of Strategic Advisory Board	6.1yrs	keine Daten	keine Daten
Douglas Drossman	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten
Jane Emerson	Independent Director	17.1yrs	US$140.27k	0.42% $ 44.4k
Anthony Lembo	Member of Scientific Advisory Board	7.8yrs	keine Daten	keine Daten
David Moatazedi	Independent Director	1.4yrs	US$114.02k	keine Daten
John Kenny	Independent Chairman of the Board	less than a year	US$87.77k	keine Daten
Catherine Coste	Independent Director	3.7yrs	US$147.77k	0.26% $ 27.4k
Brooks Cash	Chairman of Colorectal Screening Scientific Advisory Board	2.5yrs	keine Daten	keine Daten
William Whitehead	Member of the Scientific Advisory Board	no data	keine Daten	keine Daten

6.1yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrener Vorstand: BMRADie Vorstandsmitglieder gelten als erfahren (6.5 Jahre durchschnittliche Amtszeit).

Biomerica Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Jack Kenny Joins Biomerica’S Board of Directors

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Recent updates

Biomerica, Inc. Announces Infoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024

Biomerica, Inc. has filed a Follow-on Equity Offering in the amount of $5.5 million.

Biomerica Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2023)

Biomerica, Inc. Announces the Appointment of Gary Huff to Its Strategic Advisory Board

Biomerica, Inc. Appoints Jack Kenny as Chairman of the Board of Directors

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.12 loss in 2Q 2023)

Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?

Biomerica, Inc. Receives US FDA 510(k) Clearance for their Hp Detect Stool Antigen ELISA Test Product Designed to Detect Presence of H. Pylori Bacteria

First quarter 2024 earnings released: US$0.067 loss per share (vs US$0.16 loss in 1Q 2023)

Biomerica, Inc., Annual General Meeting, Dec 07, 2023

Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation

Jack Kenny Joins Biomerica’S Board of Directors

Full year 2023 earnings released: US$0.50 loss per share (vs US$0.36 loss in FY 2022)

Biomerica Inc. Receives Notice of Patent Allowance in China for A Potential Innovative Technology That Includes an Artificial Intelligence Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients

Biomerica Inc. Announces A Significant Advance in the Management of Irritable Bowel Syndrome

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.008 loss in 3Q 2022)

We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.089 loss in 2Q 2022)

Biomerica Appoints Brian E. Lacy, to the Company’s Scientific Advisory Board

Steve Sloan to Step Down as Chief Financial Officer of Biomerica, Inc

Biomerica, Inc. Announces Board Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1Q 2022)

Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test

Biomerica, Inc., Annual General Meeting, Dec 07, 2022

Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now

Biomerica, Inc. Appoints Robert Carlson as Chief Commercial Officer

Full year 2022 earnings released: US$0.36 loss per share (vs US$0.62 loss in FY 2021)

Biomerica reports FY results

Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

Price target increased to US$13.00

Biomerica, Inc Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

Biomerica, Inc. Provides Earnings Guidance for the Second Quarter Ended November 30, 2021

Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable

Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2021)

Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022

Biomerica, Inc. Expects Completion of Patient Enrollment for Its Infoods Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial This Week

Price target increased to US$13.00

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.23 loss in FY 2020)

Biomerica Announces Notice of Allowance for Patent on Product Used to Diagnose and Treat Depression

Biomerica, Inc. Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment

Biomerica (BMRA) Investor Presentation - Slideshow

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.088 loss in 3Q 2020)

Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook

Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?

New 90-day high: US$8.00

Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth

New 90-day high: US$7.50

Second quarter 2021 earnings released: US$0.13 loss per share

Earnings beat expectations, revenue disappoints

The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders

Biomerica, Inc. Receives CE Mark for its New Covid-19 Rapid Antigen Test for Detection of Covid-19 Infection

Analysts lower revenue estimates to US$8.51m

Biomerica soars as its COVID-19 antigen test wins European nod

When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?

New 90-day low: US$5.38

Biomerica, Inc. Announces Corporate Secretary Changes

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Biomerica clinical trial for IBS nears enrollment completion

How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?

Analysts update estimates

First-quarter earnings released: Revenue and earnings miss expectations

First quarter earnings released

New 90-day low: US$5.84

Analysts update estimates